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AbsTrACT
Objective to compare normothermic (35°c–36°c) 
versus hypothermic (28°c) cardiopulmonary bypass 
(cPB) in paediatric patients undergoing open heart 
surgery to test the hypothesis that normothermic cPB 
perfusion maintains the functional integrity of major 
organ systems leading to faster recovery.
Methods two single-centre, randomised controlled 
trials (known as Thermic-1 and Thermic-2, respectively) 
were carried out to compare the effectiveness and 
acceptability of normothermic versus hypothermic cPB in 
children with congenital heart disease undergoing open 
heart surgery. in both studies, the co-primary clinical 
outcomes were duration of inotropic support, intubation 
time and postoperative hospital stay.
results in total, 200 participants were recruited; 59 to 
the Thermic-1 study and 141 to the Thermic-2 study. 98 
patients received normothermic cPB and 102 patients 
received hypothermic cPB. there were no significant 
differences between the treatment groups for any of 
the co-primary outcomes: inotrope duration hr=1.01, 
95% ci (0.72 to 1.41); intubation time hr=1.14, 
95% ci (0.86 to 1.51); postoperative hospital stay 
hr=1.06, 95% ci (0.80 to 1.40). Differences favouring 
normothermia were found in urea nitrogen at 2 days 
geometric mean ratio (gMr)=0.86 95% ci (0.77 to 
0.97); serum creatinine at 3 days gMr=0.89, 95% ci 
(0.81 to 0.98); urinary albumin at 48 hours gMr=0.32, 
95% ci (0.14 to 0.74) and neutrophil gelatinase-
associated lipocalin at 4 hours gMr=0.47, 95% ci (0.22 
to 1.02), but not at other postoperative time points.
Conclusions normothermic cPB is as safe and effective 
as hypothermic cPB and can be routinely adopted as 
a perfusion strategy in low-risk infants and children 
undergoing open heart surgery.
Trial registration number isrctn93129502.
InTrOduCTIOn
Whole body cooling is an integral part of congen-
ital cardiac surgery, with most procedures being 
conducted at 28°C.1 The main rationale for body 
cooling is to protect the brain, kidneys and heart 
from ischaemic injury, by reducing the metabolic 
rate and decreasing oxygen consumption.2 In 
recent years, there has been an increasing interest 
in normothermic cardiopulmonary bypass (CPB) 
during adult cardiac surgery. The concept that 
normothermic systemic perfusion may confer 
advantages over hypothermic regimes arose from 
adult clinical experience in which an absence 
of shivering, haemodynamic stability, mimimal 
inotropes and early extubation was observed when 
patients were not cooled. This led several investi-
gators to study the effects of systemic hypothermia 
and normothermic perfusion on cellular and organ 
function.3–6 CPB perfusion temperature strategies 
and their effects on the function of several organs 
are largely the result of work carried out on adult 
humans and the conclusions cannot necessarily 
be applied directly to infants or children. Having 
demonstrated that in infants and children under-
going cardiac surgery, normothermic CPB was 
associated with reduced oxidative stress and similar 
myocardial reperfusion, renal injury and inflam-
matory response compared with hypothermic 
CPB,7 8 we hypothesised that maintaining the body 
at 35°C–37°C (normothermia) rather than cooling 
to 28°C (hypothermia) during surgery could trans-
late into better clinical outcomes. We report the 
results of two trials referred to as Thermic-1 and 
Thermic-2, respectively, designed to compare the 
clinical effectiveness of normothermic versus hypo-
thermic CPB for the repair of common congenital 
cardiac pathologies.
MeThOds
Trial design
Our study includes the Thermic-1 and Thermic-2 
trials, which are single-centre, parallel-group open 
randomised controlled trials (RCTs). Participants 
were randomly allocated to receive either hypo-
thermic or normothermic CPB in a 1:1 ratio. The 
Thermic-2 trial is registered (ISRCTN93129502) 
and details of the trial design are reported 
elsewhere.9
Participants
Patients (aged ≤18 years) having scheduled surgery 
to repair a congenital heart defect using CPB were 
eligible to participate. Patients admitted for an 
emergency operation and those requiring deep 
hypothermic circulatory arrest were excluded. 
Parents/guardians (if aged under 16 years) provided 
written informed consent, and children aged 11–15 
years provided written assent.
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Both studies were conducted at the Bristol Royal Hospital 
for Children, a regional congenital cardiac surgery centre in 
the UK. Thermic-1 recruited patients between 2002 and 2004, 
and Thermic-2 between 2012 and 2014. All paediatric cardiac 
surgeons participated in Thermic-2.
Interventions
Eligible patients were randomised to receive either normothermic 
or hypothermic CPB. CPB and anaesthetic management adhered 
strictly to a locally agreed protocol, details of which are reported 
elsewhere.7 9 In the hypothermic group, the CPB temperature was 
targeted to decrease until the nasopharyngeal body temperature 
had lowered to 28⁰C and in the normothermic group the CPB 
temperature was targeted to maintain the nasopharyngeal tempera-
ture at 35°C–36°C. Rewarming commenced after completion 
of the anatomical correction and only took place in the normo-
thermic group if the body temperature dropped below 36°C. In 
both groups, CPB was discontinued only after the participant was 
fully rewarmed to above 36⁰C. The CPB flow rate was kept at 
2.6–2.8 L/min/m2 and cold blood (4°C–6°C) cardioplegia (4:1 dilu-
tion blood/St Thomas' no. I crystalloid cardioplegia) was used for 
myocardial preservation in all patients.7 8
Outcomes
The co-primary end points were: i) duration of inotropic 
support, ii) intubation time and iii) postoperative hospital stay 
(from date of surgery to discharge from cardiac ward). Inotropic 
support was standardised; dopamine and milrinone were started 
in the operating room before weaning from CPB. Epinephrine 
was used if a low cardiac output state persisted. All the inotropic 
support drugs were weaned in the paediatric intensive care unit 
(PICU) according to the unit protocol. Secondary outcomes 
were in-hospital mortality and morbidity; blood loss and trans-
fusion requirements; postoperative echocardiographic findings; 
near-infrared spectroscopy (NIRS) during CPB, renal function 
measured by urea nitrogen, serum creatinine, urinary albumin, 
urinary creatinine, retinal binding protein (RBP), N-acetyl-β-glu-
cosaminidase (NAG) and neutrophil gelatinase-associated lipo-
calin (NGAL); cerebral function measured by glial fibrillar acidic 
protein (GFAP); neuropsychological development, assessed 
using the NEPSY-II psychometric tool (valid for participants 
aged ≥3 years and <17 years only). Unexpected serious adverse 
events (SAEs) were coded using the Medical Dictionary for 
Regulatory Activities (V.14.1; McLean, VA, USA).
Renal function was measured from serial blood and urine 
samples taken preoperatively, at cross clamp removal and 4, 24 
and 48 hours thereafter. Cerebral function was assessed preop-
eratively, at cross clamp removal and 30 min and 2, 6, 24 and 
48 hours thereafter. NEPSY-II was assessed preoperatively and at 
3 and 12 months postoperatively.
There were no changes to the outcomes during Thermic-1. 
Several secondary outcomes were added to the Thermic-2 
protocol after the start of the study: RBP, NAG and NGAL 
markers of renal function (collected for a subset of 60 patients 
not having isolated atrial septal defect surgery); and NIRS. In 
addition, the marker of brain damage was changed from protein 
S100B to GFAP, to give a more accurate measure of cerebral 
function.9 10
sample size
Full details of the power calculations are reported elsewhere.11 
Briefly, a sample size of 200 patients (100 per group) was 
required to detect reductions of: 1 day or greater in length of 
postoperative stay, 3 hours in ventilation time and 4.7 hours 
in inotropic support with 90% power, assuming a 5% level of 
statistical significance (two-tailed).
randomisation
Randomisation was stratified by age (≤1 month, 1–12 months 
and >12 months). Allocations were computer generated using 
block randomisation with varying block sizes by a statistician 
independent of the study team. A password-protected database 
concealed allocations until data had been entered to confirm 
identity and eligibility. Randomisation, which took place as 
close to the start of surgery as possible, was carried out by the 
study coordinator who placed the allocation details in an opaque 
sealed envelope before handing it to the perfusion team.
blinding
Participants and their parents/guardians were blinded to the 
treatment allocation. Staff involved in the operation were 
unblinded but the allocation was not disclosed until after the 
start of the operation. Staff caring for participants postopera-
tively were not actively informed of the participant’s allocation, 
although they could have become unblinded as they have access 
to the anaesthetic and perfusion charts which must be stored in 
the medical notes.
Echocardiographic findings were interpreted by cardiologists 
blinded to the treatment allocation. Laboratory analyses and 
the NEPSY-II test administration were carried out by blinded 
researchers. All other outcomes were ascertained directly from 
medical notes, PICU charts and electronic hospital records.11
statistical methods
Analyses were based on a prespecified statistical analysis plan (SAP) 
and performed on an intention-to-treat (ITT) basis. Outcomes 
were compared using logistic regression (binary outcomes), 
linear regression (continuous outcomes), Cox proportional 
hazards regression with appropriate censoring (time-to-event 
outcomes) or mixed-effects regression (continuous longitudinal 
outcomes); see online supplementary material for further details. 
All analyses used the hypothermic group as the reference group 
and were adjusted for trial phase (Thermic-2 vs Thermic-1) and 
age (>12 vs ≤12 months). Results are reported as effect sizes 
with 95% CIs. Serial measurements taken as part of routine care 
(eg, blood gases) are described and frequencies of adverse events 
are tabulated. Prespecified subgroup analyses by trial phase 
(Thermic-1 vs Thermic-2) were performed by adding an inter-
action term to the models. Analyses specified in the SAP but not 
in the study protocol were a) sensitivity analyses: i) excluding 
protocol deviations (all deviations, and only those deemed 
major), ii) reanalysing inotropic data including only dopamine, 
the only inotrope collected in both trial phases and b), analyses 
of each component of the primary outcome using instrumental 
variable (IV) techniques to estimate the unbiased effect of CPB 
temperature, with randomised allocation as the instrument (see 
online supplementary material). Analyses were performed in 
Stata V.14.0 (StataCorp, College Station, Texas, USA).
resulTs
recruitment
Between August 2002 and February 2004, 59 patients consented 
to participate in the Thermic-1 trial and were randomised 
(screening data unavailable). Between January 2012 and October 
2014, 449 patients were screened for inclusion in the Thermic-2 
trial, 49 of whom were ineligible. In total, 231 families of the 
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eligible patients were approached and 141 consented and their 
child was randomised (61%). Combined across both trial phases, 
98 participants were allocated to the normothermic group and 
102 to the hypothermic group (figure 1).
The primary analysis includes all randomised participants. 
There were 10 treatment cross-overs, 8 in the hypothermic group 
and 2 in the normothermic group (see online supplementary 
table S1). Thermic-1 participants were followed up to hospital 
discharge only. Thermic-2 participants were followed up for 12 
months. Safety data were collected for Thermic-2 participants 
to 12 months.
baseline data
The median age was 3.4 years (range 6 days–17.9 years); partic-
ipants in Thermic-1 were, on average, older than in Thermic-2 
(table 1 and online supplementary table S2). Overall, 95/200 
(48%) were male. Most participants scored a risk-adjusted 
congenital heart surgery (RACHS) score of 2 or 3 (163/200; 
82%). A significant proportion of participants had undergone 
cardiac surgery previously (44/200; 22%). Overall, characteris-
tics were generally well balanced across the groups.
Operative details
All measures of operative duration were longer in the normo-
thermic group than the hypothermic group by approximately 
10 min (table 2 and online supplementary table S3). These 
differences were reflected in Thermic-2, but not in Thermic-1. 
Median temperatures were similar to pre-CPB. During CPB, the 
median temperature in the normothermic group was 34.8°C vs 
28.6°C in the hypothermic group, and at cross-clamp removal 
36.1°C vs 35.0°C, respectively. By the end of CPB, temperatures 
had reverted to similar levels in the two groups. All other charac-
teristics were similar; haemodynamic instability (8/140; 6%), the 
need for cardioversion (3/187; 2%) and ischaemic changes when 
coming off CPB (2/113; 2%) were rare. All received inotropes 
when coming off CPB.
Primary outcome
Treatment estimates for the three co-primary outcomes are shown 
in figure 2. The duration of inotropic support was similar in the 
two groups (median 23 hours (IQR 16–39) in the normothermic 
group vs 21 hours (IQR 14–44) in the hypothermic group) (see 
online supplementary figure S1 and table S4). Intubation time 
was shorter in the normothermic group (median 10.6 hours (IQR 
Figure 1 Flow of participants.  *One patient was withdrawn by the clinician postrandomisation but presurgery. As the patient was happy for data 
collection to continue, they have remained in the analysis population. ASD,  atrial septal defect; PIL, patient information leaflet. 
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Congenital heart disease
5.9–25.3) vs 16.4 hours (IQR 6.1–26.6)), although this difference 
was not statistically significant (see online supplementary figure 
S2). The median postoperative hospital stay was 6.0 days in both 
groups (IQR 5.0–7.0, online supplementary figure S3). Maximum 
inotropic score and vasoactive-inotropic score12 were also similar 
(see online supplementary table S5, figure 3).
secondary outcomes
There were fewer postoperative complications in the normothermic 
group (31/96; 32% vs 42/100; 42%), although this difference 
was not statistically significant, figure 2). This difference was 
primarily due to fewer pulmonary complications and pericardial 
effusions (see online supplementary table S6). Total blood loss 
was, on average, 21% higher in the normothermic group (median 
145.0 mL (IQR 100.0–200.0) vs 117.5 mL (IQR 90.0–175.0), 
figure 2), but this did not translate into a significant difference in 
rates of postoperative blood product transfusions (70/94; 74% 
normothermic group vs 69/100; 69%) and haemoglobin levels 
were similar (see online supplementary table S6, figures S8 and 
S15). Similar proportions of patients had a decrease in left/right 
Figure 2 Primary and secondary outcomes. Duration of inotropic support was not collected in Thermic-1, and so the model only includes data from 
Thermic-2. It was not possible to adjust the inotrope duration model for age group (proportional hazards assumption was violated), and therefore 
the model is stratified by age group. Kaplan-Meier plots for each primary outcome are given in online supplementary figures S1-S3, further details 
of inotrope types are given in online supplementary table S4. Further details of the secondary outcomes are given in online supplementary table S5-
S6. GM, geometric mean; GMR, geometric mean ratio; LV, left ventricular; RV, right ventricular.
Figure 3 Comparison of mean VIS between normothermic and hypothermic groups.  GM,  geometric mean; GMR, geometric mean ratio; VIS, 
vasoactive-inotropic score.
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Congenital heart disease
ventricular function after surgery (14/37; 38% vs 15/40; 38%, 
see online supplementary table S7). Profiles over time of serial blood 
gases measurements and tests carried out as part of usual care were 
similar between the groups (see online supplementary figures S4 to 
S27). There was evidence of a treatment difference for NIRS read-
ings (see online supplementary figure S28) with lower values in the 
normothermic group (mean difference=3.63, 95% CI (−6.91 to 
−0.36); p=0.033).
Renal function measured from blood and urine samples are 
given in figure 4, online supplementary figures S29 to S31 and 
tables S8 and S9. Significant treatment time interactions (at 10% 
level) were found for urea nitrogen, serum creatinine, urinary 
albumin and NGAL, driven by treatment differences (all favouring 
the normothermic group) at one time point, namely a difference in 
urea nitrogen on day 2, serum creatinine on day 3, urinary albumin 
48 hours after cross-clamp and NGAL 4 hours after cross-clamp. 
For urinary creatinine, RBP and NAG, no statistically significant 
differences between the groups were found.
Cerebral function measured by GFAP is summarised in figure 5 
and online supplementary table S10. There were no statistically 
significant differences between the groups, although the direction 
of effects suggested slightly higher GFAP values in the normo-
thermic group. Neuropsychological developmental assessment 
(NEPSY-II) data are shown in figure 6 and online supplementary 
table S11. There were no clear differences between the groups for 
this outcome.
Ancillary analyses
Sensitivity analyses excluding protocol deviations and considering 
only dopamine usage did not substantially alter the treatment esti-
mates or change conclusions (see online supplementary tables S12 
and 13, supplementary figure S32). Subgroup analyses by trial 
phase (see online supplementary figure S33) suggested a signifi-
cant difference in treatment estimate between the two phases for 
length of stay, p value for interaction=0.079. Within Thermic-1 
the estimated HR was 1.57, 95% CI (0.93 to 2.64), suggesting 
earlier discharge in normothermic group, compared with HR 
0.90, 95% CI (0.65 to 1.26) within Thermic-2. Treatment esti-
mates were similar for other outcomes between Thermic-1 and 
Thermic-2. The IV estimates of the effect of actual CPB tempera-
ture on outcome (rather than the effect of the ‘intended’ tempera-
ture as assessed in the primary ITT analyses) for each element of 
the primary outcome are given in online supplementary table 14. 
The IV analyses produced similar findings to the ITT analyses.
Follow-up to 1 year (Thermic-2 only)
In the normothermic group, 25/70 (36%) patients experienced 
an adverse event listed in the study protocol as anticipated 
after cardiac surgery compared with 29/71 (41%) hypothermic 
patients. A total of 127 SAEs (ie, prolonged the initial hospital 
stay or resulted in a further stay in hospital) were reported in 56 
participants (66 events in 27/69 (39%) patients in the normo-
thermic group vs 61 events in 29/71 (41%) patients in the hypo-
thermic group, online supplementary table 15). There were no 
deaths within 1 year.
dIsCussIOn
The combined results of the Thermic trials suggest normothermic 
CPB is safe with no evidence of a clinical advantage in cooling 
the body of low-risk infants and children undergoing open heart 
surgery. Inotrope duration, intubation time and postoperative 
stay were similar in the two groups, a conclusion supported by 
the IV analysis. These results are clinically important given that 
Figure 4 Renal function. Further details are given in online supplementary table S8 and S9. NGAL, neutrophil gelatinase-associated lipocalin; XC, 
cross-clamp. 
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moderate hypothermia (26°C–30⁰C) is still widely used in this 
patient population. Practise among congenital cardiac surgeons 
in relation to systemic cooling is variable, with a significant 
proportion still cooling the child’s body to 26°C–30°C.1 Our 
results are consistent with Pochelet et al (RCT, n=47), who 
demonstrated that normothermic CPB protocols are reproduc-
ible and safe.13
Hypothermic CPB is still considered the most effective strategy 
for protecting the brain during surgery, aiming for a low meta-
bolic state and providing protection in case of increased blood 
return and the subsequent reduction in bypass flow or perfu-
sion failure. However, these problems are extremely rare. There 
is no cardiac surgical evidence from newborns with asphyxial 
encephalopathy that moderate hypothermia (34°C) protects 
the brain, and there is no advantage from further cooling these 
neonates.14 15 We found no significant difference in cerebral 
function between the groups (as measured by GFAP levels), and 
the neuropsychological outcomes were also similar, suggesting 
that a normothermic strategy safely protects the brain. Previous 
neurological evaluations also failed to demonstrate differences 
between the hypothermic and normothermic groups in terms of 
verbal, performance and full-scale intellectual neuropsycholog-
ical development.13
Significant differences in renal function, in favour of normo-
thermic CPB, were observed across several markers of renal 
damage. This is important as acute kidney injury is a common 
postoperative complication and independently associated with 
adverse outcomes including mortality. The higher NGAL levels 
4 hours postoperatively in the hypothermic group are indicative 
of renal tubular injury that can be exacerbated by the cooling 
and rewarming process. This phenomenon has been previ-
ously shown in adult cardiac surgery.16 We also found a trend 
towards lower levels of NAG and albumin (−14% and −37%, 
respectively) when expressed as a urinary creatinine ratio in 
Thermic-1.8
The only significant difference in favour of the hypothermic 
group was reduced blood loss, but this did not lead to a signifi-
cantly lower transfusion rate and postoperative haemoglobin 
levels were similar in the two groups. Also, there was a tendency 
towards higher NIRS readings during CPB in the hypothermic 
group, but this did not correlate with other outcomes. Evidence 
suggests that NIRS in isolation is not very sensitive in predicting 
low cardiac output and neurological dysfunction after paediatric 
cardiac surgery and should be used alongside other haemody-
namic and clinical metrics.17 18
The longer median cross-clamp time in the normothermic group 
was unexpected but is likely due to the higher proportion of more 
complex procedures in Thermic-2 (44% with RACHS score of 3 or 
4 in the normothermic group vs 28% in the hypothermic group).
strengths and limitations
Strengths include the inclusive eligibility criteria and mini-
misation of bias through concealed allocation. Within both 
trials the blood and urinary samples were analysed in a single 
hospital laboratory, thereby avoiding interlaboratory vari-
ability, and laboratory personnel were blinded to the group 
allocation.
Figure 5 Cerebral function—GFAP. GFAP could not be modelled as continuous data due to the large amount of reading that were below the lower 
limit of detection (1.5 µg/L). Therefore, data were categorised into quartiles and modelled using mixed-effects ordinal logistic regression. The model 
was stratified by age to ensure the proportional odds assumption was met. Further details are given in online supplementary table S10 . *Operation 
end was defined as cross-clamp removal. GFAP, glial fibrillary acidic protein; LLD, lower limit of detection.  
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With respect to limitations, participants were recruited from 
a single centre, limiting the generalisability of the findings. The 
two trials were carried out 10 years apart and there were differ-
ences between the two cohorts; participants in Thermic-1 were 
younger and bypass and cross-clamp times were shorter than in 
Thermic-2. There were also imbalances in preoperative characteris-
tics between the two groups in Thermic-1, which may account for 
the greater difference in length of stay between the groups observed 
in Thermic-1. Some outcomes were collected in Thermic-2 only, 
reducing the power to detect differences between the two groups 
for these outcomes. The lack of blinding of the operating room team 
and the potential for staff caring for participants postoperatively 
to determine the allocation from the medical records represents 
a further weakness. Finally, very few neonates were recruited. 
Although there is observational evidence that normothermic CPB is 
safe and effective in neonates undergoing cardiac surgery,19 20 RCT 
evidence in this subgroup is lacking.
COnClusIOn
Normothermic CPB is safe and can be adopted as a perfusion 
strategy in low-risk infants and children undergoing open heart 
surgery.
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Key messages
What is already known on this subject?
 ► In infants and children undergoing open heart surgery, 
normothermic cardiopulmonary bypass (CPB) is associated 
with reduced oxidative stress and similar myocardial 
reperfusion, renal injury and inflammatory response 
compared with hypothermic CPB.
What might this study add?
 ► We have demonstrated that in low-risk and medium-risk 
patients undergoing open heart surgery keeping the body 
warm (35°C−36°C) during CPB is clinically safe and effective.
 ► Duration of inotropes, intubation and length of stay were 
similar with a normothermic strategy as with a hypothermic 
strategy.
how might this impact on clinical practice?
 ► Normothermic CPB is safe and can be adopted as a perfusion 
strategy in low-risk to medium-risk infants and children 
undergoing open heart surgery.
Figure 6 Neuropsychological development. The figure represents the median proportion of individual NEPSY domains where the child scored at or 
above the expected level (note the number of domains scored varied according to the age of the child). This proportion was analysed using a mixed-
effects linear model. Three patients (all normothermic at 3 months) were excluded from the above analysis as <50% of the relevant NEPSY domain 
scores had been completed. Details of individual NEPSY scores are given in online supplementary table S11. MD, mean difference; NEPSY, NEPSY 
second edition psychometric tool.  
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